John W. Higuchi, a director at Lipocine Inc. (NASDAQ: LPCN), has disclosed the acquisition of $225,225 in company common stock through two separate transactions, according to a regulatory filing.
The purchases were executed on consecutive days. On November 19, 2026, Mr. Higuchi bought 75,000 shares, and on November 20, 2026, he acquired an additional 75,000 shares. The acquisition prices ranged from $1.4911 to $1.5119 per share. Following these transactions, Mr. Higuchi directly holds 391,365 shares of Lipocine common stock.
The insider buying occurred as Lipocine's shares trade near their 52-week low of $1.36, with the stock down 13% over the past week. According to InvestingPro analysis, LPCN appears undervalued at current levels, suggesting the director may be capitalizing on the recent weakness. The company's market capitalization stands at $16.61 million, and analysts maintain price targets ranging from $4 to $6 per share. InvestingPro offers 7 additional exclusive tips for LPCN subscribers, along with comprehensive Fair Value analysis.
In other recent developments, Lipocine Inc. announced the initiation of its Phase 3 BLOOM trial for LPCN1154, aimed at treating severe postpartum depression. This trial marks a significant step as the company plans to dose the first participant in the early fourth quarter of 2026. Meanwhile, H.C. Wainwright has maintained a Neutral rating for Lipocine, with a price target set at $4.00, following the trial announcement. Additionally, Lipocine has updated its sales agent fee agreement with A.G.P./Alliance Global Partners. The new agreement stipulates that the fee for sales under their existing Sales Agreement will be up to 3.0%, with potential adjustments by mutual agreement. This update was formalized in a recent SEC filing dated September 8, 2026. These developments reflect ongoing strategic moves by Lipocine in its clinical and financial operations.
Lipocine's stock closed at $1.48, down $0.0200 or 1.33%, on the day of the disclosure. In after-hours trading, the shares rose to $1.53, up $0.0500 or 3.38%.